HC Wainwright Issues Pessimistic Estimate for PLX Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – HC Wainwright cut their FY2026 earnings per share (EPS) estimates for Protalix BioTherapeutics in a report issued on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.28 per share for the year, down from their prior estimate of $0.29. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.02 EPS.

Protalix BioTherapeutics Stock Up 9.4%

Shares of NYSE PLX opened at $3.13 on Thursday. Protalix BioTherapeutics has a 12 month low of $1.65 and a 12 month high of $3.19. The business’s 50 day moving average is $2.67 and its two-hundred day moving average is $2.44. The company has a market cap of $252.19 million, a P/E ratio of -24.08 and a beta of 0.01.

Institutional Trading of Protalix BioTherapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Protalix BioTherapeutics in the second quarter worth $9,429,000. Bank of New York Mellon Corp acquired a new position in Protalix BioTherapeutics in the second quarter valued at about $543,000. Dimensional Fund Advisors LP boosted its holdings in shares of Protalix BioTherapeutics by 932.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after acquiring an additional 268,099 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Protalix BioTherapeutics by 21.3% during the first quarter. Lazard Asset Management LLC now owns 86,617 shares of the company’s stock worth $188,000 after purchasing an additional 15,224 shares during the last quarter. Finally, State of Wyoming acquired a new stake in Protalix BioTherapeutics in the 2nd quarter valued at about $138,000. 16.53% of the stock is currently owned by institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins for the treatment of rare and serious diseases. The company is headquartered in Israel and uses its proprietary ProCellEx plant-cell-based protein expression platform to produce biologic medicines. Protalix’s commercial products include Elfabrio (pegunigalsidase alfa), a treatment for adults with Fabry disease, and Elelyso (taliglucerase alfa), an enzyme replacement therapy for adults with Gaucher disease.